Holen Sie sich die Stockscreener-App
90.82
1.71%
1.53
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Warum fällt DXCM?
Forum
Prognose
Aktiensplit
Schlusskurs vom Vortag:
$89.29
Offen:
$89.805
24-Stunden-Volumen:
2.54M
Relative Volume:
0.47
Marktkapitalisierung:
$34.27B
Einnahmen:
$4.82B
Nettoeinkommen (Verlust:
$930.40M
KGV:
38.84
EPS:
2.3381
Netto-Cashflow:
$1.43B
1W Leistung:
-1.65%
1M Leistung:
+21.34%
6M Leistung:
+23.68%
1J Leistung:
+20.96%
1-Tages-Spanne:
$88.83
$90.84
1-Wochen-Bereich:
$87.51
$92.59
52-Wochen-Spanne:
$54.11
$92.59
Dexcom Inc Stock (DXCM) Company Profile
Firmenname
Dexcom Inc
Sektor
Branche
Telefon
(858) 200-0200
Adresse
6340 SEQUENCE DRIVE, SAN DIEGO, CA
Compare DXCM vs ABT, SYK, MDT, BSX, EW
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
DXCM
Dexcom Inc
|
90.82 | 34.05B | 4.82B | 930.40M | 1.43B | 2.3381 |
ABT
Abbott Laboratories
|
112.47 | 197.51B | 46.59B | 5.41B | 7.38B | 3.0938 |
SYK
Stryker Corp
|
330.69 | 125.70B | 25.27B | 3.34B | 4.57B | 8.6334 |
MDT
Medtronic Plc
|
91.23 | 118.14B | 36.36B | 4.84B | 5.43B | 3.7261 |
BSX
Boston Scientific Corp
|
46.84 | 71.55B | 20.62B | 3.56B | 3.48B | 2.3847 |
EW
Edwards Lifesciences Corp
|
90.21 | 51.78B | 6.30B | 1.07B | 1.09B | 1.8406 |
Dexcom Inc Stock (DXCM) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-03-24 | Hochstufung | Evercore ISI | In-line → Outperform |
| 2026-01-12 | Herabstufung | Barclays | Equal Weight → Underweight |
| 2025-12-02 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2025-11-25 | Eingeleitet | Evercore ISI | In-line |
| 2025-10-21 | Fortgesetzt | Stifel | Buy |
| 2025-09-08 | Herabstufung | Oppenheimer | Outperform → Perform |
| 2025-08-21 | Eingeleitet | Argus | Buy |
| 2025-06-16 | Eingeleitet | Truist | Buy |
| 2025-05-30 | Eingeleitet | Goldman | Buy |
| 2025-04-10 | Eingeleitet | Mizuho | Outperform |
| 2025-02-03 | Hochstufung | Redburn Atlantic | Neutral → Buy |
| 2025-01-16 | Hochstufung | Robert W. Baird | Neutral → Outperform |
| 2024-07-26 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2024-07-26 | Herabstufung | Robert W. Baird | Outperform → Neutral |
| 2024-05-30 | Eingeleitet | Redburn Atlantic | Neutral |
| 2024-03-12 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2023-05-30 | Fortgesetzt | Morgan Stanley | Equal-Weight |
| 2023-04-17 | Hochstufung | Raymond James | Outperform → Strong Buy |
| 2023-03-29 | Eingeleitet | UBS | Buy |
| 2023-01-26 | Eingeleitet | Wolfe Research | Outperform |
| 2022-10-18 | Eingeleitet | Barclays | Equal Weight |
| 2022-10-12 | Eingeleitet | Jefferies | Buy |
| 2022-07-15 | Eingeleitet | Bernstein | Outperform |
| 2022-03-02 | Fortgesetzt | BofA Securities | Buy |
| 2022-02-03 | Hochstufung | BTIG Research | Neutral → Buy |
| 2022-01-19 | Hochstufung | Wells Fargo | Equal Weight → Overweight |
| 2022-01-07 | Hochstufung | Guggenheim | Neutral → Buy |
| 2021-10-18 | Herabstufung | Guggenheim | Buy → Neutral |
| 2021-07-21 | Fortgesetzt | Cowen | Outperform |
| 2021-05-28 | Hochstufung | Wells Fargo | Underweight → Equal Weight |
| 2021-05-25 | Eingeleitet | Barclays | Overweight |
| 2021-04-15 | Eingeleitet | Atlantic Equities | Overweight |
| 2021-01-06 | Hochstufung | UBS | Neutral → Buy |
| 2020-10-02 | Herabstufung | Wells Fargo | Equal Weight → Underweight |
| 2020-05-27 | Bestätigt | Piper Sandler | Overweight |
| 2020-05-14 | Eingeleitet | Wells Fargo | Equal Weight |
| 2020-03-05 | Eingeleitet | Citigroup | Buy |
| 2019-11-07 | Bestätigt | Canaccord Genuity | Buy |
| 2019-11-07 | Hochstufung | Guggenheim | Neutral → Buy |
| 2019-10-23 | Eingeleitet | Stifel | Buy |
| 2018-11-28 | Eingeleitet | UBS | Neutral |
| 2018-10-19 | Hochstufung | Goldman | Sell → Neutral |
| 2018-09-12 | Hochstufung | Northland Capital | Under Perform → Market Perform |
| 2018-08-02 | Bestätigt | Canaccord Genuity | Buy |
| 2018-07-02 | Hochstufung | Raymond James | Mkt Perform → Outperform |
| 2018-06-08 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2018-05-11 | Eingeleitet | BofA/Merrill | Buy |
| 2018-05-03 | Bestätigt | Canaccord Genuity | Buy |
| 2018-04-04 | Eingeleitet | Goldman | Sell |
| 2018-04-04 | Eingeleitet | Guggenheim | Neutral |
| 2018-03-23 | Hochstufung | Robert W. Baird | Neutral → Outperform |
| 2018-01-04 | Herabstufung | Northland Capital | Market Perform → Under Perform |
| 2017-09-28 | Bestätigt | Wedbush | Outperform |
Alle ansehen
Dexcom Inc Aktie (DXCM) Neueste Nachrichten
DexCom (NASDAQ:DXCM) Reaches New 52-Week HighStill a Buy? - MarketBeat
DexCom stock hits 52-week high at 91.99 USD - Investing.com
DexCom Study Demonstrates CGM Benefits in Type 2 Diabetes - Medical Product Outsourcing
DXCM Shareholders Have Opportunity to Lead DexCom, Inc. Class Act - The National Law Review
DexCom posts $1.31B quarter as Silvant Capital opens a $5.4M stake - Dealroom
Silvant Capital Management LLC Takes $5.36 Million Position in DexCom, Inc. $DXCM - MarketBeat
Trillium Asset Management LLC Invests $3.23 Million in DexCom, Inc. $DXCM - MarketBeat
Danske Bank A S Purchases New Holdings in DexCom, Inc. $DXCM - MarketBeat
Dexcom (NASDAQ:DXCM) Combines Strong Growth With a Bullish Technical Setup - ChartMill
Dexcom stock holds close to analyst target as growth story stays intact - Ad-hoc-news.de
E Fund Management Co. Ltd. Acquires New Holdings in DexCom, Inc. $DXCM - MarketBeat
Edmond DE Rothschild Holding S.A. Invests $5.01 Million in DexCom, Inc. $DXCM - MarketBeat
Deutsche Bank AG Takes Position in DexCom, Inc. $DXCM - MarketBeat
Aurora Investment Counsel Invests $2.34 Million in DexCom, Inc. $DXCM - MarketBeat
Mitsubishi UFJ Asset Management Co. Ltd. Takes Position in DexCom, Inc. $DXCM - MarketBeat
12,080 Shares in DexCom, Inc. $DXCM Bought by Alamar Capital Management LLC - MarketBeat
Dexcom stock edges higher as Q1 2026 growth and CGM demand support valuation - Ad-hoc-news.de
Flputnam Investment Management Co. Makes New Investment in DexCom, Inc. $DXCM - insurancenewsnet.com
Performance Wealth Partners LLC Takes Position in DexCom, Inc. $DXCM - MarketBeat
GSA Capital Partners LLP Takes $1.33 Million Position in DexCom, Inc. $DXCM - MarketBeat
Global Retirement Partners LLC Purchases Shares of 20,784 DexCom, Inc. $DXCM - MarketBeat
Provident Investment Management, Inc.'s DexCom Inc(DXCM) Holding History - GuruFocus
DexCom (DXCM) Stock May Trade At A 37% Discount On Cash Flow - Yahoo Finance
DexCom Inc (MIL:1DXCM) Stock Price, Trades & News - GuruFocus
DexCom Inc. stock underperforms Monday when compared to competitors - MarketWatch
Dexcom (NASDAQ: DXCM) legal chief sells stock under 10b5-1 plan - Stock Titan
DexCom (DXCM) Rebounds On Growth Hopes, Does It Look Fully Valued? - Yahoo Finance
Dexcom stock trades at premium valuation as margins improve and targets rise - Ad-hoc-news.de
Nippon Life Global Investors Americas Inc. Buys Shares of 53,400 DexCom, Inc. $DXCM - MarketBeat
DexCom, Inc. (DXCM): Investor Outlook on a Leading Medical Device Innovator with Strong Buy Ratings - DirectorsTalk Interviews
DexCom (DXCM) Stock Sees Modest Fair Value Lift After Q2 And Clinical Updates - Yahoo Finance
Dexcom Inc (DXCM) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Bridgewater Advisors Inc. Invests $1.08 Million in DexCom, Inc. $DXCM - MarketBeat
43,005 Shares in DexCom, Inc. $DXCM Bought by SWS Partners - MarketBeat
DexCom Inc. stock underperforms Friday when compared to competitors - MarketWatch
Is Wall Street Bullish or Bearish on DexCom Stock? - Yahoo Finance
Dexcom (DXCM) director Augustinos donates 1,075 shares and reports 5,575 RSUs - Stock Titan
ETFs Investing in DexCom, Inc. Stocks - TradingView
Dexcom stock holds above $90 as strong Q2 2026 margins support a raised outlook - AD HOC NEWS
Here's How Much You'd Have If You Invested $1000 in DexCom a Decade Ago - Yahoo Finance
Citigroup Adjusts Price Target on DexCom to $105 From $88, Maintains Buy Rating - marketscreener.com
DexCom Inc. stock outperforms competitors on strong trading day - MarketWatch
Is DXCM Stock Worth Buying as Growth Improves but Valuation Stretches? - TradingView
DXCM Stock Up Nearly 35% YTD: Will the Uptrend Continue in the Rest of 2026? - TradingView
DXCM Rallies 52.5% in 3 Months. Can the Stock Keep Climbing From Here? - TradingView
DexCom (DXCM) director Bridgette Heller sells 1,012 shares in planned trade - Stock Titan
Stronger Q2 Results and Higher 2026 Outlook Might Change The Case For Investing In DexCom (DXCM) - webull.com
E. Ohman J or Asset Management AB Has $7.62 Million Position in DexCom, Inc. $DXCM - MarketBeat
DexCom stock hits 52-week high at 87.85 USD By Investing.com - Investing.com UK
DexCom Inc (DXCM) Stock Up 3.4% and Still Undervalued -- GF Scor - GuruFocus
DexCom (NASDAQ:DXCM) Reaches New 1-Year HighWhat's Next? - MarketBeat
Finanzdaten der Dexcom Inc-Aktie (DXCM)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.04%
0.35%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):